Table 2.

Univariate and multivariable analysis on factors associated with disease-free survival (DFS).

Characteristics	Class		Univariable					Multivariable
		n	Ev	HR	95% CI	p	p∗	HR	95% CI	p
Age at BC diagnosis (year)	[0–40)	65	14	1			0.01	1	–
	[40–50)	237	23	0.4	[0.21–0.78]	0.007		0.36	0.17, 0.74	0.01
	[50–60)	276	34	0.49	[0.26–0.91]	0.02		0.49	0.23, 1.03	0.06
	60+	277	47	0.73	[0.4–1.33]	0.3		0.81	0.37, 1.75	0.6
ECOG performance status	0	764	106	1			0.76
	1	90	12	1.1	[0.6–1.99]	0.76
Menopausal status	Premenopausal	254	33	1			0.99
	Postmenopausal	586	85	1	[0.67–1.5]	0.99
Clinical T stage (TNM)	T0-T1	240	23	1			0.001	1	–
	T2	348	43	1.35	[0.81–2.23]	0.24		1.24	0.74, 2.07	0.42
	T3-T4	143	35	2.55	[1.51–4.31]	0.00049		2.32	1.35, 3.98	0.0013
Clinical N stage (TNM)	N0	285	40	1			0.74
	N1	327	51	1.25	[0.83–1.9]	0.28
	N2	86	12	1.06	[0.56–2.02]	0.85
	N3	32	5	1.23	[0.49–3.12]	0.66
Lymph node involvement	1–3N+	266	20	1		0.01	0.02	1	–
	≥4N + or ≥1N + after neoadjuvant setting	589	98	1.78	[1.09–2.89]			1.7	1.00, 2.90	0.05
SBR grade	Grade I	65	5	1			0.12
	Grade II	520	69	1.61	[0.65–3.98]	0.3
	Grade III	249	42	2.17	[0.86–5.5]	0.1
IHC subtypes	ER+/PR-	137	26	1			0.09
	ER+/PR+	712	92	0.69	[0.45–1.07]	0.09
PR status	Negative	137	26	1			0.09
	Positive	712	92	0.69	[0.45–1.07]	0.09
Pathological T stage (TNM)	pT0 or pTis	4	1	1			0.04
	pT1	230	20	0.18	[0.02–1.33]	0.09
	pT2	428	62	0.3	[0.04–2.17]	0.23
	pT3	172	32	0.4	[0.05–2.9]	0.36
	pT4	18	2	0.22	[0.02–2.46]	0.22
Arm of treatment	Everolimus	401	51	1			0.64
	Placebo	454	67	1.09	[0.76–1.57]	0.64
ET duration at random assignment	≤3 years	726	100	1			0.17
	>3 years	129	18	0.7	[0.42–1.17]	0.17
ET intake timing	morning/afternoon	511	76	1			0.17	a
	evening/nighttime	344	42	0.77	[0.53–1.12]	0.17
ET agent	Aromatase inhibitor	530	78	1			0.31	a
	Tamoxifen	325	40	0.82	[0.56–1.2]	0.31

Abbreviations: ET, Endocrine therapy; EPclin: Endopredict score; IHC, Immunochemistry; pN, pathological nodal involvement; PR, Progesterone receptor; SBR, Scarff Bloom Richardson. Age is displayed as years old. p∗ is the p-value for the global test, and p represents the test of a given class versus the reference class.

^aThe association between DFS and ET intake timing is modified according to ET agent, and results in these four groups are displayed in Table S4.